ERAMET (ER7.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:ER7 • FR0000131757

68.2 EUR
+0.65 (+0.96%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Overall ER7 gets a fundamental rating of 2 out of 10. We evaluated ER7 against 42 industry peers in the Metals & Mining industry. ER7 has a bad profitability rating. Also its financial health evaluation is rather negative. ER7 has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year ER7 has reported negative net income.
  • In the past year ER7 has reported a negative cash flow from operations.
  • ER7 had positive earnings in 4 of the past 5 years.
  • Of the past 5 years ER7 4 years had a positive operating cash flow.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

1.2 Ratios

  • ER7's Return On Assets of -1.58% is on the low side compared to the rest of the industry. ER7 is outperformed by 70.45% of its industry peers.
  • ER7's Return On Equity of -9.29% is on the low side compared to the rest of the industry. ER7 is outperformed by 77.27% of its industry peers.
  • ER7's Return On Invested Capital of 0.80% is on the low side compared to the rest of the industry. ER7 is outperformed by 72.73% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ER7 is in line with the industry average of 7.74%.
  • The last Return On Invested Capital (0.80%) for ER7 is well below the 3 year average (7.29%), which needs to be investigated, but indicates that ER7 had better years and this may not be a problem.
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROIC 0.8%
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60 -80

1.3 Margins

  • ER7's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 1.91%, ER7 is doing worse than 68.18% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ER7 has declined.
  • ER7 has a Gross Margin of 68.15%. This is amongst the best in the industry. ER7 outperforms 88.64% of its industry peers.
  • In the last couple of years the Gross Margin of ER7 has grown nicely.
Industry RankSector Rank
OM 1.91%
PM (TTM) N/A
GM 68.15%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ER7 is destroying value.
  • ER7 has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for ER7 has been increased compared to 5 years ago.
  • Compared to 1 year ago, ER7 has an improved debt to assets ratio.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • ER7 has an Altman-Z score of 1.13. This is a bad value and indicates that ER7 is not financially healthy and even has some risk of bankruptcy.
  • ER7 has a Altman-Z score of 1.13. This is in the lower half of the industry: ER7 underperforms 72.73% of its industry peers.
  • ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 2.03, ER7 is doing worse than 88.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Altman-Z 1.13
ROIC/WACC0.09
WACC9.29%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • A Current Ratio of 1.54 indicates that ER7 should not have too much problems paying its short term obligations.
  • With a Current ratio value of 1.54, ER7 is not doing good in the industry: 70.45% of the companies in the same industry are doing better.
  • ER7 has a Quick Ratio of 1.06. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.06, ER7 perfoms like the industry average, outperforming 43.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.06
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for ER7 have decreased strongly by -219.63% in the last year.
  • Measured over the past years, ER7 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -64.00% on average per year.
  • The Revenue has decreased by -6.91% in the past year.
  • The Revenue has been decreasing by -4.39% on average over the past years.
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%

3.2 Future

  • The Earnings Per Share is expected to decrease by -25.91% on average over the next years. This is quite bad
  • ER7 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.00% yearly.
EPS Next Y-282.67%
EPS Next 2Y-47.83%
EPS Next 3Y-25.91%
EPS Next 5YN/A
Revenue Next Year-0.95%
Revenue Next 2Y5.78%
Revenue Next 3Y7%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ER7. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ER7. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ER7 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.89
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

  • A cheap valuation may be justified as ER7's earnings are expected to decrease with -25.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-47.83%
EPS Next 3Y-25.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

2

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.98%, ER7 has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.66, ER7 pays a bit more dividend than its industry peers.
  • ER7's Dividend Yield is comparable with the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.98%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
ER7.DE Yearly Dividends per shareER7.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 1 2 3

5.3 Sustainability

  • The earnings of ER7 are negative and hence is the payout ratio. ER7 will probably not be able to sustain this dividend level.
DP-44.33%
EPS Next 2Y-47.83%
EPS Next 3Y-25.91%
ER7.DE Yearly Income VS Free CF VS DividendER7.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

More info and screens

Find the best dividend stocksShow peers with best dividend

ERAMET

FRA:ER7 (2/6/2026, 7:00:00 PM)

68.2

+0.65 (+0.96%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)10-30
Earnings (Next)02-18
Inst Owners15.34%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.96B
Revenue(TTM)2.88B
Net Income(TTM)-97.00M
Analysts52.73
Price Target61.41 (-9.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.98%
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.57%
PT rev (3m)17.3%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)24.02%
EPS NY rev (3m)0.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 1.88
P/tB 3.63
EV/EBITDA 16.89
EPS(TTM)-3.42
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.58%
ROE -9.29%
ROCE 1.16%
ROIC 0.8%
ROICexc 0.95%
ROICexgc 1.09%
OM 1.91%
PM (TTM) N/A
GM 68.15%
FCFM N/A
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexgc growth 3Y-56.22%
ROICexgc growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF N/A
Debt/EBITDA 10.29
Cap/Depr 403.31%
Cap/Sales 21.11%
Interest Coverage 0.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.06
Altman-Z 1.13
F-Score2
WACC9.29%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-219.63%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-282.67%
EPS Next 2Y-47.83%
EPS Next 3Y-25.91%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year-0.95%
Revenue Next 2Y5.78%
Revenue Next 3Y7%
Revenue Next 5YN/A
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year8.9%
EBIT Next 3Y30.86%
EBIT Next 5YN/A
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.


Can you provide the valuation status for ERAMET?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.


What is the profitability of ER7 stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.


Can you provide the financial health for ER7 stock?

The financial health rating of ERAMET (ER7.DE) is 2 / 10.


How sustainable is the dividend of ERAMET (ER7.DE) stock?

The dividend rating of ERAMET (ER7.DE) is 2 / 10 and the dividend payout ratio is -44.33%.